Home/Filings/4/0001193125-25-192818
4//SEC Filing

Hallal David 4

Accession 0001193125-25-192818

CIK 0001808865other

Filed

Aug 28, 8:00 PM ET

Accepted

Aug 29, 4:30 PM ET

Size

9.2 KB

Accession

0001193125-25-192818

Insider Transaction Report

Form 4
Period: 2025-08-29
Hallal David
Director
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-08-2925,1400 total
    Exercise: $2.95Common Stock (25,140 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-08-29146,1600 total
    Exercise: $4.24Common Stock (146,160 underlying)
Footnotes (2)
  • [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,
  • [F2](Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

Documents

1 file

Issuer

iTeos Therapeutics, Inc.

CIK 0001808865

Entity typeother

Related Parties

1
  • filerCIK 0001457477

Filing Metadata

Form type
4
Filed
Aug 28, 8:00 PM ET
Accepted
Aug 29, 4:30 PM ET
Size
9.2 KB